- Home
- OLMA vs TOVX Comparison
OLMA vs TOVX Comparison
Compare OLMA & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLMA
- TOVX
- Stock Information
- Founded
- OLMA 2006
- TOVX 2001
- Country
- OLMA United States
- TOVX United States
- Employees
- OLMA N/A
- TOVX N/A
- Industry
- OLMA Biotechnology: Pharmaceutical Preparations
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- OLMA Health Care
- TOVX Health Care
- Exchange
- OLMA Nasdaq
- TOVX Nasdaq
- Market Cap
- OLMA 299.7M
- TOVX 3.8M
- IPO Year
- OLMA 2020
- TOVX 2006
- Fundamental
- Price
- OLMA $4.37
- TOVX $0.44
- Analyst Decision
- OLMA Strong Buy
- TOVX Hold
- Analyst Count
- OLMA 4
- TOVX 1
- Target Price
- OLMA $24.50
- TOVX N/A
- AVG Volume (30 Days)
- OLMA 1.1M
- TOVX 1.6M
- Earning Date
- OLMA 08-05-2025
- TOVX 08-12-2025
- Dividend Yield
- OLMA N/A
- TOVX N/A
- EPS Growth
- OLMA N/A
- TOVX N/A
- EPS
- OLMA N/A
- TOVX N/A
- Revenue
- OLMA N/A
- TOVX N/A
- Revenue This Year
- OLMA N/A
- TOVX N/A
- Revenue Next Year
- OLMA N/A
- TOVX N/A
- P/E Ratio
- OLMA N/A
- TOVX N/A
- Revenue Growth
- OLMA N/A
- TOVX N/A
- 52 Week Low
- OLMA $2.86
- TOVX $0.40
- 52 Week High
- OLMA $16.62
- TOVX $7.37
- Technical
- Relative Strength Index (RSI)
- OLMA 48.24
- TOVX 33.64
- Support Level
- OLMA $4.45
- TOVX $0.42
- Resistance Level
- OLMA $4.73
- TOVX $0.55
- Average True Range (ATR)
- OLMA 0.31
- TOVX 0.03
- MACD
- OLMA 0.03
- TOVX 0.02
- Stochastic Oscillator
- OLMA 52.75
- TOVX 11.23
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.